Literature DB >> 33125829

Structural Basis of the Modulation of the Voltage-Gated Calcium Ion Channel Cav 1.1 by Dihydropyridine Compounds*.

Shuai Gao1, Nieng Yan1.   

Abstract

1,4-Dihydropyridines (DHP), the most commonly used antihypertensives, function by inhibiting the L-type voltage-gated Ca2+ (Cav ) channels. DHP compounds exhibit chirality-specific antagonistic or agonistic effects. The structure of rabbit Cav 1.1 bound to an achiral drug nifedipine reveals the general binding mode for DHP drugs, but the molecular basis for chiral specificity remained elusive. Herein, we report five cryo-EM structures of nanodisc-embedded Cav 1.1 in the presence of the bestselling drug amlodipine, a DHP antagonist (R)-(+)-Bay K8644, and a titration of its agonistic enantiomer (S)-(-)-Bay K8644 at resolutions of 2.9-3.4 Å. The amlodipine-bound structure reveals the molecular basis for the high efficacy of the drug. All structures with the addition of the Bay K8644 enantiomers exhibit similar inactivated conformations, suggesting that (S)-(-)-Bay K8644, when acting as an agonist, is insufficient to lock the activated state of the channel for a prolonged duration.
© 2020 The Authors. Angewandte Chemie International Edition published by Wiley-VCH GmbH.

Entities:  

Keywords:  cryo-electron microscopy; inhibitors; nanodiscs; structural biology; voltage-gated calcium ion channels

Year:  2020        PMID: 33125829     DOI: 10.1002/anie.202011793

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  9 in total

Review 1.  Ligand binding at the protein-lipid interface: strategic considerations for drug design.

Authors:  Jian Payandeh; Matthew Volgraf
Journal:  Nat Rev Drug Discov       Date:  2021-07-13       Impact factor: 84.694

2.  Targeting the tamoxifen receptor within sodium channels to block osteoarthritic pain.

Authors:  Megan M McCollum; Megan Larmore; Shingo Ishihara; Leo C T Ng; Louise F Kimura; Eduardo Guadarrama; My C Ta; Thuy N Vien; Grant B Frost; Karl A Scheidt; Rachel E Miller; Paul G DeCaen
Journal:  Cell Rep       Date:  2022-08-23       Impact factor: 9.995

3.  Structural basis for pore blockade of human voltage-gated calcium channel Cav1.3 by motion sickness drug cinnarizine.

Authors:  Xia Yao; Shuai Gao; Nieng Yan
Journal:  Cell Res       Date:  2022-04-27       Impact factor: 46.297

Review 4.  Voltage-Gated Ca2+-Channel α1-Subunit de novo Missense Mutations: Gain or Loss of Function - Implications for Potential Therapies.

Authors:  Jörg Striessnig
Journal:  Front Synaptic Neurosci       Date:  2021-03-03

Review 5.  P-Loop Channels: Experimental Structures, and Physics-Based and Neural Networks-Based Models.

Authors:  Denis B Tikhonov; Boris S Zhorov
Journal:  Membranes (Basel)       Date:  2022-02-16

6.  Structure, gating, and pharmacology of human CaV3.3 channel.

Authors:  Lingli He; Zhuoya Yu; Ze Geng; Zhuo Huang; Changjiang Zhang; Yanli Dong; Yiwei Gao; Yuhang Wang; Qihao Chen; Le Sun; Xinyue Ma; Bo Huang; Xiaoqun Wang; Yan Zhao
Journal:  Nat Commun       Date:  2022-04-19       Impact factor: 17.694

7.  Structure of the Human BK Ion Channel in Lipid Environment.

Authors:  Lige Tonggu; Liguo Wang
Journal:  Membranes (Basel)       Date:  2022-07-31

8.  Structural modeling of the hERG potassium channel and associated drug interactions.

Authors:  Jan Maly; Aiyana M Emigh; Kevin R DeMarco; Kazuharu Furutani; Jon T Sack; Colleen E Clancy; Igor Vorobyov; Vladimir Yarov-Yarovoy
Journal:  Front Pharmacol       Date:  2022-09-16       Impact factor: 5.988

9.  Structure of human Cav2.2 channel blocked by the painkiller ziconotide.

Authors:  Shuai Gao; Xia Yao; Nieng Yan
Journal:  Nature       Date:  2021-07-07       Impact factor: 49.962

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.